Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats
- PMID: 10389992
- PMCID: PMC2362986
- DOI: 10.1038/sj.bjc.6690335
Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats
Abstract
An isolated limb perfusion (ILP) model using soft tissue sarcoma-bearing rats was used to study prerequisites for an effective ILP, such as oxygenation of the perfusate, temperature of the limb, duration of the perfusion and concentration of tumour necrosis factor (TNF). Combination of 50 microg TNF and 40 microg melphalan demonstrated synergistic activity leading to a partial and complete response rate of 71%. In comparison to oxygenated ILP, hypoxia was shown to enhance anti-tumour activity of melphalan alone and TNF alone but not of their combined use. Shorter perfusion times decreased anti-tumour responses. At a temperature of 24-26 degrees C, anti-tumour effects were lost, whereas temperatures of 38-39 degrees C or 42-43 degrees C resulted in higher response rates. However, at 42-43 degrees C, local toxicity impaired limb function dramatically. Synergy between TNF and melphalan was lost at a dose of TNF below 10 microg in 5 ml perfusate. We conclude that the combination of TNF and melphalan has strong synergistic anti-tumour effects in our model, just as in the clinical setting. Hypoxia enhanced activity of melphalan and TNF alone but not the efficacy of their combined use. For an optimal ILP, minimal perfusion time of 30 min and minimal temperature of 38 degrees C was mandatory. Moreover, the dose of TNF could be lowered to 10 microg per 5 ml perfusate, which might allow the use of TNF in less leakage-free or less inert perfusion settings.
Similar articles
-
Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions.Br J Cancer. 2000 Nov;83(9):1176-82. doi: 10.1054/bjoc.2000.1447. Br J Cancer. 2000. PMID: 11027431 Free PMC article.
-
Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies.J Natl Cancer Inst. 2004 Nov 3;96(21):1603-10. doi: 10.1093/jnci/djh300. J Natl Cancer Inst. 2004. PMID: 15523089
-
A human melanoma xenograft in a nude rat responds to isolated limb perfusion with TNF plus melphalan.Surgery. 2003 Apr;133(4):420-8. doi: 10.1067/msy.2003.113. Surgery. 2003. PMID: 12717360
-
Effectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities.Int J Hyperthermia. 2008 May;24(3):193-203. doi: 10.1080/02656730701868387. Int J Hyperthermia. 2008. PMID: 18392998 Review.
-
Isolated limb perfusion for in-transit melanoma metastases: melphalan or TNF-melphalan perfusion?J Surg Oncol. 2014 Mar;109(4):338-47. doi: 10.1002/jso.23552. Epub 2014 Jan 9. J Surg Oncol. 2014. PMID: 24403098 Review.
Cited by
-
Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions.Br J Cancer. 2000 Nov;83(9):1176-82. doi: 10.1054/bjoc.2000.1447. Br J Cancer. 2000. PMID: 11027431 Free PMC article.
-
Tumour necrosis factor and cancer.Nat Rev Cancer. 2009 May;9(5):361-71. doi: 10.1038/nrc2628. Epub 2009 Apr 3. Nat Rev Cancer. 2009. PMID: 19343034 Review.
-
Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery.Br J Cancer. 2006 Dec 18;95(12):1663-9. doi: 10.1038/sj.bjc.6603461. Epub 2006 Nov 14. Br J Cancer. 2006. PMID: 17106443 Free PMC article.
-
Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma.Curr Treat Options Oncol. 2007 Dec;8(6):417-27. doi: 10.1007/s11864-007-0044-y. Epub 2007 Dec 8. Curr Treat Options Oncol. 2007. PMID: 18066703 Free PMC article. Review.
-
Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity.Br J Cancer. 2002 Apr 8;86(7):1174-9. doi: 10.1038/sj.bjc.6600169. Br J Cancer. 2002. PMID: 11953868 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources